Iván Gómez Herrero

  • ivan.gomez@unican.es
  • 942 206 799 ext. 25906
  • Chronic Inflammatory and Autoimmune Diseases
  • Inmunology
  • Department of Cell & Molecular Signalling

​Chronic Inflammatory and Autoimmune Diseases

Research lines

Our research project addresses the role of BAMBI (BMP and Activin Membrane-Bound Inhibitor), a plasma membrane-bound inhibitor of TGFβ signaling, in the control of Immune System activity. We have previously demonstrated that BAMBI forms part of a rheostat-like molecular device that through the direct regulation of TGFβ signalling strength and the indirect control of IL-2 signalling, influences the capacity of newly activated CD4+ T cells to functionally differentiate into anti-inflammatory regulatory T cells (Treg) and pro-inflammatory Th17 cells. In this regard, BAMBI deficiency protects mice against the development of autoimmune arthritis by Treg- and TGFβ-dependent mechanisms. Based in these findings, we have developed an inhibitory anti-mouse and anti-human BAMBI mAb, clone B101-37, that exhibits preventive and therapeutic activities in different experimental murine models of psoriasis and arthritis. This technology has been protected by a patent, owned by the CSIC and the Universidad de Cantabria that has been licensed to Inhibitec-Anticuerpos S.L., a recently created start-up company that plans to position B101.37 as a new gold standard in the management of psoriatic arthritis. Our present research activity is:

  1. To explore the role of BAMBI in mucosal immunity and microbiota composition and its possible involvement in in the development of inflammatory bowel disease and colon cancer associated to chronic inflammation.
  2. The role of BAMBI in humoral immune responses.
  3. In the context of Inhibitec-Anticuerpos, we plan to humanize B101-37 as a first step to its introduction into clinical trials.

From a technological point of view, our research group has a large experience in the induction and clinical and immunological study of several murine models of autoimmune/inflammatory diseases including systemic lupus erythematosus, collagen type-II induced autoimmune arthritis, Imiquimod-induced psoriasis, Saccharomyces Cerevisiae mannan-induced psoriatic arthritis and dextran sodium sulphate-induced colitis.


 1-    Title: Anticuerpos monoclonales frente a BAMBI y uso para tratamiento de enfermedades inflamatorias. International Patent PCT/ES2016/070852. Extended to EC (16870040.9), USA (060418INTEFSW00000022090528).

    Inventors: Jesús Merino Pérez; Ramón Merino Pérez.

   Owners: Consejo Superior de Investigaciones Científicas/Universidad de Cantabria.

 2-     Title: Methods for treating and diagnosing disease. Patente Internacional WO 2012/113785.

    Inventors: Juan Saus; Fernando Revert; Ramón Merino Pérez; Jesús Merino Pérez.

    Owner:Fibrostatin S.L.

Startup Companies

      Name: Inhibitec-Anticuerpos S.L.

      Date of Registration:05/03/2019

Ramón Merino Pérez (IP)

View more